Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net loss	$ (1,411,620)	$ (9,085,268)	$ (3,892,932)	$ (11,964,663)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	278,969	56,739	579,734	99,295
Depreciation expense	25,000	22,000	53,104	46,394
Noncash lease expense			2,816	358
Reverse recapitalization issuance costs in excess of gross proceeds		6,566,821		6,566,821
Change in fair value of derivative warrant liabilities	(72,591)	(1,454,440)	(99,353)	(1,454,440)
Changes in operating assets and liabilities:
Accounts receivable			(215,680)	(100,000)
Prepaid expenses and other current assets			561,579	(101,413)
Due from related parties				286
Accounts payable			487,297	983,634
Accrued expenses and other current liabilities			(267,866)	400,166
Security deposits				(11,000)
Deferred revenue			(107,970)
Net cash used in operating activities			(2,899,271)	(5,534,562)
Cash flows from investing activities:
Purchases of property and equipment			(94,009)	(3,453)
Net cash flows used in investing activities			(94,009)	(3,453)
Cash flows from financing activities:
Proceeds from January 2023 PIPE, net of issuance costs			1,985,301
Net proceeds from Transaction and Maxim Private Placement				3,307,162
Proceeds from the Arena Purchase Agreement			49,158
Repayment of insurance premium financing			(518,552)
Proceeds from exercise of stock options			1,443	659,501
Net cash provided by financing activities			1,517,350	3,966,663
Net decrease in cash, cash equivalents and restricted cash			(1,475,930)	(1,571,352)
Cash, cash equivalents and restricted cash at beginning of period			2,002,232	6,560,140
Cash, cash equivalents, and restricted cash at end of period	526,302	4,988,788	526,302	4,988,788
Supplemental information:
Cash and cash equivalents	476,302	4,938,788	476,302	4,938,788
Restricted cash	50,000	50,000	50,000	50,000
Total cash, cash equivalents, and restricted cash shown in statements of cash flows	$ 526,302	$ 4,988,788	526,302	4,988,788
Supplemental disclosure of noncash investing and financing activities:
Fixed asset additions in accounts payable				25,154
Stock issuance costs in accounts payable and accrued expenses and other current liabilities			383,616
Acquisition of right-of-use asset				162,634
Conversion of convertible preferred stock into common stock				20,857,453
Financing of insurance premiums			647,799	1,516,000
Issuance of common stock to settle stock issuance costs				3,443,750
Issuance of common stock in exchange for services by the Company's Board of Directors			68,125
Issuance of Series A preferred stock to settle stock issuance costs				910,000
Accretion on convertible preferred stock			$ 172,688	201,168
Issuance of Series A preferred stock to settle underwriting fees payable assumed in Transaction				3,395,389
Derivative warrant liabilities assumed in Transaction				$ 2,286,379